Vaccine for stem cell donors to prevent CMV
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be having a stem cell transplant from a related donor who is a close match (8/8 HLA markers).
- You must have a history of CMV (cytomegalovirus), verified by a blood test showing antibodies.
- Your cancer must be one of these types: lymphoma, myelodysplastic syndrome, certain leukemias, chronic myelogenous leukemia, or myeloproliferative disorders (NOT multiple myeloma).
- Your heart, lungs, liver, and kidneys must be working well enough, as shown by standard tests.
- The donor cannot have certain health issues like sickle cell disease, heart disease, or active infections such as HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.